A Phase 4 interventional study of Ketorolac Tromethamine 0.45% and bromfenac 0.09% in Cataracts, sponsored by Frank A. Bucci, Jr., M.D.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-03.
Sponsored by Frank A. Bucci, Jr., M.D. · Phase 4, Interventional, and Treatment
Approximately 126 subjects scheduled to undergo cataract surgery by phacoemulsification, will be randomized in an even allocation (1:1:1) to either Acuvail, Xibrom, or Nevanac. Subjects will be instructed to begin dosing the study medication in the operative eye the day before surgery and continue dosing on the day of surgery. Beginning one hour before surgery, 1 drop of study medication will be instilled by operating room staff approximately every 15 minutes for a total of 3 doses. At the designated time a paracentesis will be performed at the start of the cataract procedure and at least 0.15 cc of aqueous humor will be collected. The sample will be immediately stored on dry ice and shipped to a laboratory for analysis.
1,701 studies on the registry are indexed under Cataract; 230 are open to participants now.
This study's enrollment of 126 is above the median of 80 across 1,155 interventional studies indexed under Cataract.
Browse Cataract studies →Frank A. Bucci, Jr., M.D. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Acuvail to be given preoperatively. One drop 2 times daily (BID), 1 day pre op and day of surgery 3 doses prior to surgery
Drug: Ketorolac Tromethamine 0.45%
Xibrom to be given 1 drop 2 times daily (BID) the day before surgery and 3 doses the day of surgery prior to surgery
Drug: bromfenac 0.09%
One day before surgery 1 drop 2 times daily (BID), then 3 doses the day of surgery
Drug: nepafenac 0.1%
One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery
Also known as: Acuvail
One day pre operative 1 drop BID then 3 doses pre op day of surgery
Also known as: Xibrom
One drop BID, 1 day pre operative and then 3 doses the day of surgery
Also known as: Nevanac
Peak Aqueous Penetration
Time frame: day 4 of treatment
| Milestone | Acuvail | Xibrom | Nevanac |
|---|---|---|---|
| Started | 42 | 42 | 42 |
| Completed | 42 | 41 | 38 |
| Not completed | 0 | 1 | 4 |
| ng/ml | Acuvail | Xibrom | Nevanac |
|---|---|---|---|
| Peak Aqueous Penetration | 688.87 ± 749.6 | 67.64 ± 62.4 | 447.1 ± 225.7 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Acuvail | — | 0/42 (0%) | 0/42 (0%) |
| Xibrom | — | 0/42 (0%) | 0/42 (0%) |
| Nevanac | — | 0/42 (0%) | 0/42 (0%) |
| Age, Categorical(Participants) | Acuvail | Xibrom | Nevanac | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 21 | 18 | 15 | 54 |
| >=65 years | 21 | 24 | 27 | 72 |
| Age Continuous(years) | Acuvail | Xibrom | Nevanac | Total |
|---|---|---|---|---|
| Mean | 75 ± 30 | 72 ± 31 | 74 ± 29 | 74 ± 29 |
| Sex: Female, Male(Participants) | Acuvail | Xibrom | Nevanac | Total |
|---|---|---|---|---|
| Female | 26 | 26 | 29 | 81 |
| Male | 16 | 16 | 13 | 45 |
| Region of Enrollment(participants) | Acuvail | Xibrom | Nevanac | Total |
|---|---|---|---|---|
| United States | 42 | 42 | 42 | 126 |
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Frank A. Bucci, Jr., M.D.